Coronary stent patients need individualized DAPT duration
EXPERT OPINION FROM THE AHA SCIENTIFIC SESSIONS
The question of DAPT duration “is a question that clinicians will need to have with each of their patients, especially those who are tolerating DAPT,” commented Dr. Richard A. Chazal, an interventionalist and medical director of the Heart and Vascular Institute at the Lee Memorial Health System in Fort Myers, Fla.
Dr. Montalescot has been a consultant to more than a dozen pharmaceutical and device companies, including companies that market antiplatelet drugs. Dr. Antman has received grant support from Daiichi Sankyo. Dr. Mauri received personal fees from Medtronic, Recur, St. Jude, and Biotronik, and grant support from nine device manufacturer and drug companies. Dr. Schulz-Schüpke, Dr. Zuckerman, Dr. Becker, and Dr. Chazal had no relevant disclosures.
On Twitter@mitchelzoler
*CORRECTION, 11/18/2014: An earlier version of this article misstated the treatment length in patients with a high ischemia risk.
